Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors.

Furubayashi N, Negishi T, Iwai H, Nagase K, Taguchi K, Shimokawa M, Nakamura M.

Indian J Urol. 2017 Jan-Mar;33(1):64-69. doi: 10.4103/0970-1591.194786.

2.

Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

Walter SD, de Koning HJ, Hugosson J, Talala K, Roobol MJ, Carlsson S, Zappa M, Nelen V, Kwiatkowski M, Páez Á, Moss S, Auvinen A; ERSPC Cause of Death Committees.

Br J Cancer. 2017 Jan 3;116(1):141-148. doi: 10.1038/bjc.2016.378. Epub 2016 Nov 17.

PMID:
27855442
3.

Active surveillance for intermediate-risk prostate cancer.

Dall'Era MA, Klotz L.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):1-6. doi: 10.1038/pcan.2016.51. Epub 2016 Nov 1. Review.

4.

Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes.

van der Poel HG, van den Bergh RC.

Int Braz J Urol. 2016 May-Jun;42(3):413-7. doi: 10.1590/S1677-5538.IBJU.2016.03.03. No abstract available.

5.

Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.

Price AJ, Travis RC, Appleby PN, Albanes D, Barricarte Gurrea A, Bjørge T, Bueno-de-Mesquita HB, Chen C, Donovan J, Gislefoss R, Goodman G, Gunter M, Hamdy FC, Johansson M, King IB, Kühn T, Männistö S, Martin RM, Meyer K, Neal DE, Neuhouser ML, Nygård O, Stattin P, Tell GS, Trichopoulou A, Tumino R, Ueland PM, Ulvik A, de Vogel S, Vollset SE, Weinstein SJ, Key TJ, Allen NE; Endogenous Hormones, Nutritional Biomarkers, and Prostate Cancer Collaborative Group.

Eur Urol. 2016 Dec;70(6):941-951. doi: 10.1016/j.eururo.2016.03.029. Epub 2016 Apr 6.

6.

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base--a refined prostate cancer trajectory.

Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P.

Int J Epidemiol. 2016 Feb;45(1):73-82. doi: 10.1093/ije/dyv305. Epub 2015 Dec 11. No abstract available.

7.

Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms-A whole of population study.

Ta AD, Papa NP, Lawrentschuk N, Millar JL, Syme R, Giles GG, Bolton DM.

Prostate Int. 2015 Sep;3(3):75-9. doi: 10.1016/j.prnil.2015.06.004. Epub 2015 Jul 17.

8.

Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer.

Kim JH, Hong SK.

Biomed Res Int. 2015;2015:475920. doi: 10.1155/2015/475920. Epub 2015 Aug 3. Review.

9.

Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Morash C, Tey R, Agbassi C, Klotz L, McGowan T, Srigley J, Evans A.

Can Urol Assoc J. 2015 May-Jun;9(5-6):171-8. doi: 10.5489/cuaj.2806.

10.

Population-based study of long-term functional outcomes after prostate cancer treatment.

Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P.

BJU Int. 2016 Jun;117(6B):E36-45. doi: 10.1111/bju.13179. Epub 2015 Jun 23.

11.

Causes of death in men with localized prostate cancer: a nationwide, population-based study.

Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, Stattin P.

BJU Int. 2016 Mar;117(3):507-14. doi: 10.1111/bju.13059. Epub 2015 May 15.

12.

Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Canadian Task Force on Preventive Health Care, Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, Shaw E, Dunfield L, Tonelli M.

CMAJ. 2014 Nov 4;186(16):1225-34. doi: 10.1503/cmaj.140703. Epub 2014 Oct 27. No abstract available.

13.

Post-treatment MRI aspects of photodynamic therapy for prostate cancer.

Kulik M, Nedelcu C, Martin F, Lebdai S, Rousselet MC, Azzouzi AR, Aubé C.

Insights Imaging. 2014 Dec;5(6):697-713. doi: 10.1007/s13244-014-0359-8. Epub 2014 Oct 7.

14.

Analysis of regional bone scan index measurements for the survival of patients with prostate cancer.

Kalderstam J, Sadik M, Edenbrandt L, Ohlsson M.

BMC Med Imaging. 2014 Jul 10;14:24. doi: 10.1186/1471-2342-14-24.

15.

Recent advances in imaging-guided interventions for prostate cancers.

Wu X, Zhang F, Chen R, Zheng W, Yang X.

Cancer Lett. 2014 Jul 28;349(2):114-9. doi: 10.1016/j.canlet.2014.04.015. Epub 2014 Apr 24. Review.

16.

Prostate cancer mortality in areas with high and low prostate cancer incidence.

Stattin P, Carlsson S, Holmström B, Vickers A, Hugosson J, Lilja H, Jonsson H.

J Natl Cancer Inst. 2014 Mar;106(3):dju007. doi: 10.1093/jnci/dju007. Epub 2014 Mar 7. Erratum in: J Natl Cancer Inst. 2014 Aug;106(8):dju193 doi:10.1093/jnci/dju193.

17.

Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.

Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G, Wiklund P.

BMJ. 2014 Feb 26;348:g1502. doi: 10.1136/bmj.g1502.

18.

Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer.

Chiang AS, Loblaw DA, Jethava V, Sethukavalan P, Zhang L, Vesprini D, Mamedov A, Nam R, Klotz L.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):450-3. doi: 10.5489/cuaj.262.

19.

Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, McMahon PM.

Ann Intern Med. 2013 Jun 18;158(12):853-60. doi: 10.7326/0003-4819-158-12-201306180-00002.

20.

Supplemental Content

Support Center